|Calculated MW||This protein is fused with 6×His tag at the C-terminus, has a calculated MW of 24.7 kDa. The predicted N-terminus is Val 35. DTT-reduced Protein migrates as 45-75 kDa due to different glycosylation.|
|Other Names||CD80, B7, B7-1, B7.1, BB1, CD28LG, CD28LG1, LAB7|
|Results||Measured by its ability to induce IL2 secretion by Jurkat human acute T cell leukemia cells. The ED50 for this effect is typically 0.01 - 0.1 µg/mL in the presence of phytohaemagglutinin.|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
B7-1 and B7-2, together with their receptors CD28 and CTLA4, constitute one of the dominant co-stimulatory pathways that regulate T and Bcell responses. Although both CTLA4 and CD28 can bind to the same ligands, CTLA4 binds to B71 and B72 with a 20 100 fold higher affinity than CD28 and is involved in the downregulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.
Freeman G.J.,et al.J. Immunol. 143:2714-2722(1989).
Selvakumar A.,et al.Immunogenetics 36:175-181(1992).
Kakoulidou M.,et al.Scand. J. Immunol. 66:529-537(2007).
Muzny D.M.,et al.Nature 440:1194-1198(2006).
Freeman G.J.,et al.J. Exp. Med. 174:625-631(1991).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.